The annual Russell Index reconstitution is a once-a-year process in which FTSE Russell reviews the US equity market and reshuffles companies across its indexes, based largely on market capitalization.
According to analysts, California biopharmaceutical firm BridgeBio is expected to graduate to the Russell 1000 following the June 26 reconstitution, marking a significant milestone in the company's growth.
The expected graduation to the Russell 1000 reflects BridgeBio's sustained growth since its founding in 2015 and suggests the market is increasingly recognizing the scale and maturity of its pipeline and commercial outlook.
BridgeBio currently stands out in the R2000 index with a market cap of over $13 billion, roughly 12 times the index median, making it one of the largest companies in the index.
The expected graduation to the R1000 is a long-term positive for the stock, as it expands BridgeBio's investor base. However, the move could create some short-term selling pressure at reconstitution, as some funds explicitly follow the R2000 and are obliged to sell when companies leave the index.
Analysts have emphasized that this would only cause short-term volatility and is a technical dynamic rather than a reflection of BridgeBio's fundamentals. They highlighted that any volatility would be a good entry point for investors.
BridgeBio has strong fundamentals, and its expected graduation to the Russell 1000 on June 26 reflects its continued growth, reinforcing a positive outlook for the company.
BridgeBio is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Palo Alto, California. It operates an integrated model that spans target identification, preclinical research, clinical development, and commercialization, aiming to streamline the process from bench to bedside.
The company has won three FDA approvals to date, with Attruby (Acoramidis) being used to treat adults with cardiomyopathy caused by wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM). In a 30-month clinical study, people treated with Attruby did significantly better than those who did not receive it, reducing the risk of death and hospitalization.
In May this year, BridgeBio presented late-stage data showing patients taking Attruby had a 34% lower rate of cardiovascular hospitalizations than those on tafamidis, the ATTR-CM treatment manufactured by Pfizer and sold under the name Vyndamax.
Attruby generated $362.4 million in its first full year on the market, and Jefferies analysts forecast peak annual sales for the drug of more than $3 billion. The ATTR-CM treatment market is projected to reach $16.5 billion by 2030.
BridgeBio's current pipeline is extensive and spans investigational drugs which aim to treat various conditions, including Canavan disease, Hypochondroplasia, achondroplasia, and Early-Stage Variant Transthyretin Amyloidosis. Three of these programs have positive Phase 3 results and are now at or near FDA submission.
The company currently has a market cap of over $13 billion and $502.1 million in full year revenue in 2025. Its expected graduation to the Russell 1000 is a significant milestone in its growth and reinforces a positive outlook for the company.
